Fixed combination of amlodipine/atorvastatin: From mechanisms to trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 6, 2013, Pages 544-549

  Ivanovic, Branislava ^a,b   Tadic, Marijana ^c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c University Clinical Hospital Center Dr Dragisa Misovic Dedinje   (Serbia)

Author keywords

amlodipine atorvastatin; cardiovascular disease; dyslipidemia; fixed combination; hypertension

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PLACEBO;

ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; METABOLIC SYNDROME X; MYALGIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINUSITIS; TREATMENT FAILURE;

AMLODIPINE/ATORVASTATIN; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; FIXED COMBINATION; HYPERTENSION;

AMLODIPINE; ANTICHOLESTEREMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; DRUG SYNERGISM; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MEDICATION ADHERENCE; PYRROLES; RISK FACTORS;

EID: 84887598843     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413492907     Document Type: Article

References (32)

1. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC Cardiovasc Disord. 2010 ; 10: 29-39
2. Tunstall-Pedoe H, Chen R, Kramarz P. Prevalence of individuals with both raised blood pressure and raised cholesterol in WHO MONICA Project population surveys 1989-97. Pharmacoepidemiol Drug Saf. 2004 ; 13 (suppl 1). S307 - S308
3. Kannel WB. Fifty years of Framingham study contributions to understanding hypertension. J Hum Hypertens. 2000 ; 14 (2). 83-90
4. Williams B, Wilson K, Lacey L, et al. The prevalence and management of patients with co-existing hypertension and hypercholesterolaemia in the UK. Eur Heart J. 2004 ; 25 (suppl). 528-529
5. Ivanović B, Simić D, Matić D, Kalimanovska- Oštrić D, Avramović D. Uloga udruženog delovanja arterijske hipertenzije i hiperholesterolemije u patogenezi ateroskleroze. Arterijska hipertenzija - Odabrane teme 2. Belgrade, Serbia: Medicinski fakultet u Beogradu ; 2006: 187-201.
6. Granger DN, Rodrigues SF, Yildirim A, Senchenkova EY. Microvascular responses to cardiovascular risk factors. Microcirculation. 2010 ; 17 (3). 192-205
7. Meyer G, Merval R, Tedgui A. Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Circ Res. 1996 ; 79 (3). 532-540
8. Toikka JO, Laine H, Ahotupa M, et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension. 2000 ; 36 (6). 929-936
9. Sposito C.. Emerging insights into hypertension and dyslipidaemia synergies. Eur Heart J. 2004 ; (suppl 6). G8 - G12
10. Cohn JN, Wilson DJ, Neutel J, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009 ; 22 (2). 137-144
11. Ivanović B. Lečenje arterijske hipertenzije. Kardiologija. Ostojić M Kanjuh V Belesnin B, ed. Belgrade, Serbia: Zavod za izdavanje udžbenika u Beogradu ; 2011: 477-483.
12. Aslam F, Haque A, Lee V, Foody J. Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination. Patient Prefer Adherence. 2009 ; 3: 61-66
13. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008 ; 4 (3). 673-681
14. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin GEMINI study). J Clin Hypertens (Greenwich). 2005 ; 7 (5). 264-273
15. Hobbs FD, Gensini G, Mancini GB, et al. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol. 2006 ; 110 (2). 242-250
16. Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc. 2008 ; 83 (1). 35-45
17. Ferdinand KC, Flack JM, Saunders E, et al. Amlodipine/atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2009 ; 11 (10). 585-593
18. Ivanovic BA, Tadic MV, Simic DV. Are all criteria of metabolic syndrome equally harmful?. Acta Cardiol. 2011 ; 66 (2). 189-196
19. Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens. 2009 ; 23 (3). 196-210
20. Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich). 2009 ; 11 (1). 22-30
21. Grimm R, Malik M, Yunis C, Sutradhar S, Kursun A, TOGETHER Investigators. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag. 2010 ; 6: 261-271
22. Oliver S, Jones J, Leonard D, Crabbe A, Delkhah Y.. Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. J Clin Hypertens (Greenwich). 2011 ; 13 (8). 598-604
23. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011 ; 27 (4). 821-833
24. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trail-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 ; 361 (9364). 1149-1158
25. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 ; 366 (9489). 895-906
26. Clunn GF, Sever PS, Hughes AD. Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and calcium channel blockers. Int J Cardiol. 2010 ; 139 (1). 62-66
27. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 121-137
28. Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 ; 8 (8). 571-581
29. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997 ; 157 (21). 2413-2446
30. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003 ; 289 (19). 2560-2572
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106: 3143-3421
32. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol. 2007 ; 47 (12). 1555-1569